Dihydropteridione intermediate compounds

Details Dihydropteridione intermediate compounds Dihydropteridione intermediate compounds

2007-12-18

2009-06-16

Berch, Mark L (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Four or more ring nitrogens in the bicyclo ring system

C560S029000, C544S257000, C544S329000

Reexamination Certificate

active

07547780

ABSTRACT:
Disclosed are new dihydropteridinones of general formula (I)whereby the groups L, R1, R2, R3, R4and R5have the meanings given in the claims and specification, the isomers thereof, processes for preparing these dihydropteridinones and their use as pharmaceutical compositions.

REFERENCES:
patent: 5167949 (1992-12-01), Ferrand et al.
patent: 5424311 (1995-06-01), Billhardt-Troughton et al.
patent: 5698556 (1997-12-01), Chan
patent: 6806272 (2004-10-01), Bauer et al.
patent: 6861422 (2005-03-01), Hoffmann et al.
patent: 7241889 (2007-07-01), Hoffmann et al.
patent: 2003/0130286 (2003-07-01), Denny et al.
patent: 2005/0014760 (2005-01-01), Hoffmann et al.
patent: 2005/0014761 (2005-01-01), Hoffmann et al.
patent: 2006/0004014 (2006-01-01), Hoffmann et al.
patent: 2006/0009457 (2006-01-01), Hoffmann et al.
patent: 2006/0025411 (2006-02-01), Hoffmann et al.
patent: 2006/0046989 (2006-03-01), Grauert et al.
patent: 2006/0058311 (2006-03-01), Munzert et al.
patent: 2006/0074088 (2006-04-01), Munzert et al.
patent: 2006/0079503 (2006-04-01), Schwede et al.
patent: 2458699 (2003-03-01), None
patent: 2517020 (2004-10-01), None
patent: 0399856 (1990-11-01), None
patent: 0429149 (1991-05-01), None
patent: 0119825 (2001-03-01), None
patent: 02057261 (2002-07-01), None
patent: 02076954 (2002-10-01), None
patent: 02076985 (2002-10-01), None
patent: 03020722 (2003-03-01), None
patent: 03093249 (2003-11-01), None
patent: 2004014899 (2004-02-01), None
patent: 2004076454 (2004-09-01), None
Masuda, et al., Oncogene (2003) 22, 1012-1023.
Ito, et al., “Polo-like kinase 1 (PLK1) expression with cell proliferative activity and cdc2 expression in malignant lymphoma of the thyroid” Anticancer Research 2004, vol. 24, No. 1, pp. 259-263 (hhtp://cat.inist.fr/?aModele=afficheN&cpsidt=15622521 Nov. 17, 2006—Abstract).
Mito, et al., “Expression of Polo-Like Kinase (PLK1) in non-Hodgkin's lymphomas,” Leuk. Lymphoma, Feb. 2005, 46(1): 225-31 (PubMed abstract).
Verschuren, et al., “The cell cycle and how it is steered by Kaposi's sarcoma-associated herpesvirus cyclin” J. Gen. Virology (2004), 85, pp. 1347-1361.
Tor Ahlenius, Listing of cardiovascular disorders/diseases, Karolinska Instiutet Library, Stockholm, Sweden, http://www.mic.ki.se/diseases/c14.html, pp. 1-34, Apr. 2007.
Wolf, Donald E., et al., “The Structure of Rhizopterin”, J. Am. Chem. Soc., vol. 69, pp. 2753-2759, 1947.
Ferrand, G. et al: “Synthesis and potential antiallergic activity of new pteridinones and related compounds.” European Journal of Medicinal Chemistry, vol. 31, #4, 1996, pp. 273-280.
Kimball, S.D., et al; Ann. Reports Med. Chem., vol. 36,2001, pp. 139-148.
Savelli, F.& Boido, A;. “Heterocyclic System Part II-Synthesis of New Pyrido [1′2′:4,5] pyrazino [3,2-d] pyrimidines”; Bollettino Chimico Farmaceutico, 131(8), 309-12, Sep. 1992.
Katherine Arnold, “Collaboration to Play Key Role in NCI's Future, Director Says” Journal of the National Cancer Institute, Jun. 5, 2002, pp. 790-792, vol. 94, No. 11. Http://jncicancerspectrum.oxfordjournals.org/cgi/content/full/jnci;94/11/790.
The Merck Manual of Medical Information—Home Edition, Section 17, Parasitic Infections, Chapter 184 on the web site http://www.merck.com/mrkshared/mmanual—home/sec17/184.jsp, downloaded on Nov. 26, 2003.
US Office Action mailed Dec. 10, 2003, U.S. Appl. No. 10/226,710.
US Office Action mailed Apr. 28, 2004, U.S. Appl. No. 10/374,876.
International Search Report, Reference No. PCT/EP2005/008990, 2005.

Affiliated with

Also associated with

Rating

Dihydropteridione intermediate compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dihydropteridione intermediate compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dihydropteridione intermediate compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4101651